PharmAthene (PIP) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	116.05M
Change in market value of derivative instruments
Bad debt (recovery) expense
Depreciation and amortization
Compensatory option expense
Non cash interest expense on debt
Accounts receivable	-153.67K
Prepaid expenses and other current assets	-328.33K
Accounts payable	93.42K
Accrued expenses and other liabilities	479.75K
Net cash used in operating activities
Purchases of property and equipment	-30.5K
Proceeds from sales or maturities of short term investments
Net cash provided by investing activities
Change in restricted cash requirements
Net proceeds from issuance of common stock and warrants
Net cash provided by financing activities
Effects of exchange rates on cash	-2.38K
Increase (decrease) in cash and cash equivalents	53.54M
Cash and cash equivalents, at beginning of period	15.57M
Cash and cash equivalents, at end of period	69.11M
Cash paid for interest	0
Cash paid for income taxes

Entities mentioned with PIP

View All Entities